O	0	5	Phase
O	6	8	II
O	9	13	dose
O	13	14	-
O	14	21	finding
O	22	27	study
O	28	30	of
B-intervention	31	42	balugrastim
O	43	45	in
O	46	52	breast
O	53	59	cancer
O	60	68	patients
O	69	78	receiving
O	79	95	myelosuppressive
O	96	108	chemotherapy
O	108	109	.

O	110	121	Balugrastim
O	122	124	is
O	125	126	a
O	127	131	once
O	131	132	-
O	132	135	per
O	135	136	-
O	136	141	cycle
O	141	142	,
O	143	148	fixed
O	148	149	-
O	149	153	dose
O	154	165	recombinant
O	166	173	protein
O	174	184	comprising
O	185	190	human
O	191	196	serum
O	197	204	albumin
O	205	208	and
O	209	220	granulocyte
O	221	227	colony
O	227	228	-
O	228	239	stimulating
O	240	246	factor
O	247	252	under
O	253	264	development
O	265	268	for
O	269	279	prevention
O	280	282	of
O	283	289	severe
O	290	301	neutropenia
O	302	304	in
O	305	311	cancer
O	312	320	patients
O	321	330	receiving
O	331	347	myelosuppressive
O	348	360	chemotherapy
O	360	361	.

O	362	366	This
O	367	372	phase
O	373	375	II
O	375	376	,
O	377	388	multicenter
O	388	389	,
O	390	396	active
O	396	397	-
O	397	407	controlled
O	407	408	,
O	409	413	dose
O	413	414	-
O	414	421	finding
O	422	427	pilot
O	428	433	study
O	434	443	evaluated
O	444	455	balugrastim
O	456	462	safety
O	463	466	and
O	467	475	efficacy
O	476	482	versus
O	483	496	pegfilgrastim
O	497	499	in
O	500	506	breast
O	507	513	cancer
O	514	522	patients
O	523	532	scheduled
O	533	535	to
O	536	543	receive
O	544	560	myelosuppressive
O	561	573	chemotherapy
O	574	577	and
O	578	590	investigated
O	591	594	two
O	595	600	doses
O	601	605	with
O	606	613	similar
O	614	622	efficacy
O	623	625	to
O	626	639	pegfilgrastim
O	640	643	for
O	644	645	a
O	646	656	subsequent
O	657	662	phase
O	663	666	III
O	667	672	study
O	672	673	.

O	674	682	Patients
O	683	691	received
O	692	696	four
O	697	703	cycles
O	704	706	of
O	707	718	doxorubicin
O	718	719	/
O	719	728	docetaxel
O	729	741	chemotherapy
O	742	745	and
O	746	750	with
O	751	755	each
O	756	766	successive
O	767	772	cycle
O	773	777	were
O	778	788	randomized
O	789	801	sequentially
O	802	804	to
O	805	815	escalating
O	816	821	doses
O	822	824	of
O	825	836	balugrastim
O	837	838	[
O	838	840	30
O	841	842	(
O	842	843	n
O	844	845	=
B-intervention-participants	846	848	11
O	848	849	)
O	849	850	,
O	851	853	40
O	854	855	(
O	855	856	n
O	857	858	=
B-intervention-participants	859	861	21
O	861	862	)
O	862	863	,
O	864	866	or
O	867	869	50
O	870	872	mg
O	873	874	(
O	874	875	n
O	876	877	=
B-intervention-participants	878	880	20
O	880	881	)
O	881	882	]
O	883	885	or
O	886	887	a
O	888	893	fixed
O	894	898	dose
O	899	901	of
B-control	902	915	pegfilgrastim
O	916	917	[
O	917	918	6
O	919	921	mg
O	922	923	(
O	923	924	n
O	925	926	=
B-control-participants	927	929	26
O	929	930	)
O	930	931	]
O	932	936	post
O	936	937	-
O	937	949	chemotherapy
O	949	950	.

O	951	962	Balugrastim
O	963	968	doses
O	969	973	were
O	974	983	escalated
O	984	986	as
O	987	994	planned
O	994	995	.

O	996	999	The
B-outcome	1000	1009	incidence
I-outcome	1010	1012	of
I-outcome	1013	1020	adverse
I-outcome	1021	1027	events
O	1028	1031	was
O	1032	1039	similar
O	1040	1045	among
O	1046	1049	the
O	1050	1061	balugrastim
O	1062	1068	groups
O	1069	1072	and
O	1073	1080	between
O	1081	1084	all
O	1085	1096	balugrastim
O	1097	1102	doses
O	1103	1106	and
O	1107	1120	pegfilgrastim
O	1120	1121	.

O	1122	1125	The
O	1126	1130	most
O	1131	1141	frequently
O	1142	1150	reported
O	1151	1158	adverse
O	1159	1165	events
O	1166	1170	were
B-outcome	1171	1182	neutropenia
O	1182	1183	,
B-outcome	1184	1192	alopecia
O	1192	1193	,
O	1194	1197	and
B-outcome	1198	1204	nausea
O	1204	1205	.

O	1206	1212	During
O	1213	1218	cycle
O	1219	1220	1
O	1220	1221	,
B-outcome	1222	1228	severe
I-outcome	1229	1240	neutropenia
O	1241	1242	(
O	1242	1250	absolute
O	1251	1261	neutrophil
O	1262	1267	count
O	1268	1270	of
O	1271	1272	<
O	1272	1273	0
O	1273	1274	.
O	1274	1275	5
O	1276	1277	×
O	1278	1280	10
O	1280	1281	(
O	1281	1282	9
O	1282	1283	)
O	1283	1284	/
O	1284	1285	L
O	1285	1286	)
O	1287	1295	occurred
O	1296	1298	in
B-iv-bin-percent	1299	1301	40
O	1301	1302	,
B-iv-bin-percent	1303	1305	67
O	1305	1306	,
O	1307	1310	and
B-iv-bin-percent	1311	1313	50
I-iv-bin-percent	1314	1315	%
O	1316	1319	and
B-outcome	1320	1327	febrile
I-outcome	1328	1339	neutropenia
O	1340	1348	occurred
O	1349	1351	in
B-iv-bin-percent	1352	1354	20
I-iv-bin-percent	1354	1355	.
I-iv-bin-percent	1355	1356	0
O	1356	1357	,
B-iv-bin-percent	1358	1359	9
I-iv-bin-percent	1359	1360	.
I-iv-bin-percent	1360	1361	5
O	1361	1362	,
O	1363	1366	and
B-iv-bin-percent	1367	1369	10
I-iv-bin-percent	1369	1370	.
I-iv-bin-percent	1370	1371	0
I-iv-bin-percent	1372	1373	%
O	1374	1376	of
O	1377	1385	patients
O	1386	1395	receiving
O	1396	1407	balugrastim
O	1408	1410	30
O	1410	1411	,
O	1412	1414	40
O	1414	1415	,
O	1416	1419	and
O	1420	1422	50
O	1423	1425	mg
O	1425	1426	,
O	1427	1439	respectively
O	1439	1440	;
O	1441	1443	in
O	1444	1452	patients
O	1453	1462	receiving
O	1463	1476	pegfilgrastim
O	1476	1477	,
B-cv-bin-percent	1478	1480	48
I-cv-bin-percent	1481	1482	%
O	1483	1494	experienced
B-outcome	1495	1501	severe
I-outcome	1502	1513	neutropenia
O	1514	1517	and
B-cv-bin-percent	1518	1519	8
I-cv-bin-percent	1520	1521	%
O	1522	1533	experienced
B-outcome	1534	1541	febrile
I-outcome	1542	1553	neutropenia
O	1553	1554	.

B-outcome	1555	1563	Duration
I-outcome	1564	1566	of
I-outcome	1567	1573	severe
I-outcome	1574	1585	neutropenia
I-outcome	1586	1587	(
I-outcome	1587	1590	DSN
I-outcome	1590	1591	)
O	1592	1595	for
O	1596	1600	each
O	1601	1610	treatment
O	1611	1616	group
O	1617	1620	was
B-iv-cont-mean	1621	1622	0
I-iv-cont-mean	1622	1623	.
I-iv-cont-mean	1623	1624	9
O	1624	1625	,
B-iv-cont-mean	1626	1627	1
I-iv-cont-mean	1627	1628	.
I-iv-cont-mean	1628	1629	6
O	1629	1630	,
B-iv-cont-mean	1631	1632	1
I-iv-cont-mean	1632	1633	.
I-iv-cont-mean	1633	1634	1
O	1634	1635	,
O	1636	1639	and
B-cv-cont-mean	1640	1641	0
I-cv-cont-mean	1641	1642	.
I-cv-cont-mean	1642	1643	9
I-cv-cont-mean	1644	1648	days
O	1648	1649	,
O	1650	1662	respectively
O	1662	1663	.

O	1664	1666	In
O	1667	1670	the
O	1671	1680	remaining
O	1681	1686	three
O	1687	1699	chemotherapy
O	1700	1706	cycles
O	1706	1707	,
B-outcome	1708	1711	DSN
O	1712	1715	was
O	1716	1717	≤
O	1717	1718	1
O	1719	1722	day
O	1723	1729	across
O	1730	1733	all
O	1734	1743	treatment
O	1744	1750	groups
O	1750	1751	.

O	1752	1763	Balugrastim
O	1764	1766	50
O	1767	1769	mg
O	1770	1773	was
O	1774	1784	comparable
O	1785	1787	to
O	1788	1801	pegfilgrastim
O	1802	1804	in
O	1805	1810	terms
O	1811	1813	of
O	1814	1820	safety
O	1821	1824	and
O	1825	1832	overall
O	1833	1841	efficacy
O	1842	1844	in
O	1845	1851	breast
O	1852	1858	cancer
O	1859	1867	patients
O	1868	1877	receiving
O	1878	1894	myelosuppressive
O	1895	1907	chemotherapy
O	1907	1908	.
